The Federal Circuit reversed a grant of summary judgment of non-infringement, holding that the term “substantially flattened surfaces” in a tampon applicator patent means surfaces materially flatter than the cylindrical barrel — not surfaces that are flat within a manufacturing tolerance
The Federal Circuit reversed the district court and invalidated Merck’s Fosamax once-weekly dosing patent as obvious, holding that prior art newsletter articles clearly disclosed once-weekly alendronate dosing, that the claim term ‘about’ retains its ordinary meaning of ‘appr
The Federal Circuit held that a patentee’s listing of a patent in the FDA Orange Book does not, by itself, create the reasonable apprehension of suit necessary for a generic drug maker to maintain a Hatch-Waxman declaratory judgment action challenging the patent’s validity or non-infring
The Federal Circuit affirmed that farmers who saved and replanted seeds from Monsanto’s patented Roundup Ready soybeans infringed Monsanto’s plant patents — holding that patent exhaustion did not apply to second-generation seeds and that Monsanto’s technology use agreements validly
In an en banc decision, the Federal Circuit eliminated the rule that a patent infringer who invokes attorney-client privilege faces an adverse inference of willful infringement, substantially reshaping the willfulness landscape.
The Federal Circuit affirmed rejection of a patent application for lack of novelty, holding that a slide presentation displayed for several days at professional conferences constitutes a ‘printed publication’ under 35 U.S.C. § 102(b) based on public accessibility — even without distribut
The Federal Circuit vacated summary judgment of non-infringement, holding that the claim term ‘operatively connected’ means components must be connected in a way that permits them to perform their designated function — not that they must be physically attached in a unitary structure.
The Federal Circuit established that a generic drug company’s filing of an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification cannot, by itself, constitute willful patent infringement or justify enhanced damages and attorney fees.
The Federal Circuit affirmed a jury verdict that LabCorp indirectly infringed Metabolite’s patent on a method of detecting vitamin B12 and folate deficiency by measuring and correlating homocysteine levels, a case that later reached the Supreme Court and raised fundamental questions about pate
The Federal Circuit held that a patent applicant’s cancellation of an independent claim and rewriting of a dependent claim as a new independent claim during prosecution triggers prosecution history estoppel, creating a presumptive bar to capturing the surrendered subject matter through the doc